|
Acute myocardial infarction
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Inhibition of RASSF1 expression alleviated cardiomyocytes apoptosis induced by hypoxia in vitro and reduced cardiomyocytes apoptosis after AMI in vivo.
|
31595551 |
2020 |
|
Hypertensive disease
|
0.010 |
Biomarker
|
group |
BEFREE |
A RASSF1A-HIF1α loop drives Warburg effect in cancer and pulmonary hypertension.
|
31086178 |
2019 |
|
Myocarditis
|
0.010 |
Biomarker
|
disease |
BEFREE |
These findings indicate that myeloid RASSF1A antagonizes I/R-induced myocardial inflammation and suggest that RASSF1A may be a promising target in immunomodulatory therapy for the management of acute heart injury.
|
31311858 |
2019 |
|
Ovarian Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Aberrant Promoter Hypermethylation of RASSF1a and BRCA1 in Circulating Cell-Free Tumor DNA Serves as a Biomarker of Ovarian Carcinoma.
|
31653147 |
2019 |
|
Asymmetric Septal Hypertrophy
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
The most important finding is that compared with the ASH group of patients, the expression levels of all three TSG proteins, RUNX3, GSTP1, and RASSF1, were significantly lower in the NASH group of patients (p < .001 in all three molecules).
|
30951700 |
2019 |
|
Zika Virus Infection
|
0.010 |
PosttranslationalModification
|
disease |
BEFREE |
<b>Results & conclusion:</b> ZIKV infection altered the DNA methylation of several genes such as WWTR1 (TAZ) and RASSF1 of Hippo signaling pathway which regulates organ size during brain development, and decreased the expression of several centrosomal-related microcephaly genes, and genes involved in stemness and differentiation in human neural progenitor cells.
|
31234652 |
2019 |
|
Cardiac fibrosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
In conclusion, RASSF1-AS1 inhibits the translation of RASSF1A to exacerbate cardiac fibrosis in mice, indicating a potential application of RASSF1-AS1 as a therapy target for cardiac fibrosis.
|
30571844 |
2019 |
|
HER2-positive carcinoma of breast
|
0.010 |
Biomarker
|
disease |
BEFREE |
In order to investigate if aberrant promoter methylation of p16, BRCA1 and RASSF1A genes contributes to biological behavior of triple-negative breast cancer (TNBC), marked as the most aggressive phenotype of breast cancer, we compared the hypermethylation pattern between TNBC and ER+PR+Her2- breast cancer.
|
30003738 |
2019 |
|
Solitary Pulmonary Nodule
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
The expression of RUNX3 and RASSF1A in malignant SPN tissues was lower than that in benign SPN tissues.
|
31436249 |
2019 |
|
Refractory Cytopenia of Childhood
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
In the RCC cancerous tissue, TIMP-3 levels increased 1.3 times and RASSF1A levels increased 1.4 times compared to the corresponding levels in non-cancerous tissues, and there was no statistically significant difference in these values.
|
31773698 |
2019 |
|
Nonalcoholic Steatohepatitis
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
The different expression of tumor suppressors, RASSF1A, RUNX3, and GSTP1, in patients with alcoholic steatohepatitis (ASH) vs non-alcoholic steatohepatitis (NASH).
|
30951700 |
2019 |
|
Multiple Chronic Conditions
|
0.010 |
Biomarker
|
disease |
BEFREE |
The present study aimed to investigate the role of Multi-drug resistance gene (MDR1), Placental glutathione S-transferase-P1 (GSTP1), Lung resistance protein (LRP) and Ras association domain family member 1 (RASSF1A) in primary epithelial ovarian cancer (PEOC).
|
31579424 |
2019 |
|
Fatty Liver Disease
|
0.010 |
Biomarker
|
disease |
BEFREE |
The most important finding is that compared with the ASH group of patients, the expression levels of all three TSG proteins, RUNX3, GSTP1, and RASSF1, were significantly lower in the NASH group of patients (p < .001 in all three molecules).
|
30951700 |
2019 |
|
Triple-Negative Breast Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Co-methylated p16 and RASSF1A genes were more frequent in the TNBC than in ER+PR+Her2- group (20; 32.8% vs. 10; 14.3%, p=0.0225).
|
30003738 |
2019 |
|
HER2-negative breast cancer
|
0.010 |
Biomarker
|
disease |
BEFREE |
In order to investigate if aberrant promoter methylation of p16, BRCA1 and RASSF1A genes contributes to biological behavior of triple-negative breast cancer (TNBC), marked as the most aggressive phenotype of breast cancer, we compared the hypermethylation pattern between TNBC and ER+PR+Her2- breast cancer.
|
30003738 |
2019 |
|
Pelvic Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
Hypermethylated gene promoters were significantly more prevalent in renal pelvic tumors (p < 0.001), specifically for TMEFF2, GDF15, RASSF1A, SALL3 and ABCC6 (all p < 0.05).
|
29587736 |
2018 |
|
Tongue Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
In addition, we found that RASSF1A promoter hypermethylation exerted higher frequency in the tongue tumor than other site tumor in mouth (RASSF1A, tongue tumor vs other site tumor in mouth, unmethylation vs methylation, OR = 0.65, 95%CI = 0.44-0.98).
|
29538221 |
2018 |
|
B-Cell Lymphomas
|
0.010 |
AlteredExpression
|
group |
BEFREE |
The effects of miR‑181a on cell division cycle 25A (CDC25A), cyclin A2, cyclin D1, p21, Bcl‑2‑associated X protein (Bax) and B‑cell lymphoma‑2 (Bcl‑2) protein levels were assessed in gastric cancer cell lines. miR‑181a directly interacted with the 3'‑untranslated region of RASSF1A and downregulated RASSF1A protein expression.
|
30106448 |
2018 |
|
Malignant neoplasm of mouth
|
0.010 |
GeneticVariation
|
group |
BEFREE |
To clarify the effect of RAS association domain family protein 1a (RASSF1A), retinoic acid receptor beta (RARβ), and E-cadherin (CDH1) promoter hypermethylation on the risk of oral cancer, we performed this meta-analysis.
|
29538221 |
2018 |
|
Embryonal Carcinoma
|
0.010 |
PosttranslationalModification
|
disease |
BEFREE |
Significant differences in CRIPTO, MGMT and RASSF1A methylation levels were depicted between pure forms and matched mixed components of seminomas and embryonal carcinoma.
|
30418048 |
2018 |
|
Congenital contractural arachnodactyly
|
0.010 |
Biomarker
|
disease |
BEFREE |
In the present study, the results obtained from our previously published methylation array were analyzed and 10 candidate genes involved in DNA repair [protein phosphatase 4 catalytic subunit (PPP4C)], apoptosis [runt related transcription factor 3 (RUNX3), interferon regulatory factor 4 (IRF4), ubiquitin C‑terminal hydrolase L1 (UCHL1) and tumor protein p53 inducible protein 3 (TP53I3)], cell proliferation [cyclin D2 (CCND2) and Ras association domain family member 1 (RASSF1)], drug metabolism [aldehyde dehydrogenase 1 family member A3 (ALDH1A3) and solute carrier family 29 member 1 (SLC29A1)] and angiogenesis [human immunodeficiency virus‑1 tat interactive protein 2 (HTATIP2)] were selected for quantification of their methylation levels in 54 CCA and 19 adjacent normal tissues using methylation‑sensitive high‑resolution melting.
|
29359783 |
2018 |
|
Atypical Teratoid Rhabdoid Tumor
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Next, hmDNA levels (RASSF1A qMSP) in stored urine samples of patients suffering from bladder cancer (n = 10) or non-small cell lung cancer (NSCLC; n = 10) were measured at day 0 and 7 upon storage with and without the addition of 40mM EDTA and/or 20 μl/ml Penicillin Streptomycin (PenStrep) at RT and 4°C.
|
30142219 |
2018 |
|
Tumor Angiogenesis
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
Our results demonstrate for the first time that AGP induces RASSF1A expression in colon cancer cells and is dependent on angiogenesis signaling events.
|
30045022 |
2018 |
|
Lymphoproliferative Disorders
|
0.010 |
GeneticVariation
|
group |
BEFREE |
MTX-BLPD patients without hypermethylated RAS-associated domain family-1A (RASSF1A) or O <sup>6</sup> -methyl guanine-DNA methyltransferase (MGMT) had significantly better prognosis than those with hypermethylation of those genes (P = 0.033).
|
27864689 |
2017 |
|
Gestational Trophoblastic Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
The aim of the study was to evaluate the effectiveness of placental-specific markers, extracellular fetal DNA (sex-determining region Y and hypermethylated RASSF1A sequences) and circulating C19MC microRNAs (miR-516-5p, miR-517-5p, miR-518b, miR-520a-5p, miR-520h, miR-525, and miR-526a) for the diagnosis and consecutive follow-up of gestational trophoblastic disease/neoplasia.
|
28381180 |
2017 |